Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Up 2,205.1% in March

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 225,900 shares, a growth of 2,205.1% from the February 28th total of 9,800 shares. Currently, 14.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,470,000 shares, the short-interest ratio is presently 0.2 days.

Sonoma Pharmaceuticals Trading Down 8.3 %

Sonoma Pharmaceuticals stock opened at $2.88 on Friday. Sonoma Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $9.37. The stock has a market cap of $4.65 million, a price-to-earnings ratio of -0.72 and a beta of 1.56. The company’s 50-day moving average price is $2.73 and its two-hundred day moving average price is $2.85.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings data on Wednesday, February 5th. The company reported ($0.59) EPS for the quarter. Sonoma Pharmaceuticals had a negative net margin of 26.82% and a negative return on equity of 68.98%. Research analysts expect that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.